Eli Lilly director Fyrwald granted 8.5 shares

Eli Lilly director J. Erik Fyrwald received a small deferred stock unit award, lifting his direct holdings to about 75.5 thousand shares.

Available on EDGAR 09/22/2026 - 04:13 PM EDT Accepted by SEC EDGAR 09/22/2026 - 04:12 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

ELI LILLY & Co (LLY) reported that director J. Erik Fyrwald acquired an award of 8.513 shares of common stock on September 21, 2026, valued at $1,164.89 per share. Following this grant, Fyrwald’s directly held position is 75,536.1308 shares, which have been deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares after his separation from service.

Insider Trade Summary

Grant/Award: 8.513 shares

Grant/Award 1 txn

Insider Fyrwald J Erik

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	8.513	$1,164.89	$10K

Holdings After Transaction: Common Stock — 75,536.1308 shares (Direct)

Holdings Before and After: Common Stock, 75,527.6178 to 75,536.1308 shares (Direct)

Footnotes (1)

1. F1. At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.

Key Figures

Shares acquired: 8.513 shares Reported value per share: $1,164.89 per share Total direct holdings after transaction: 75,536.1308 shares +1 more

4 metrics

Shares acquired 8.513 shares Grant of common stock on September 21, 2026

Reported value per share $1,164.89 per share Value used for the September 21, 2026 stock award

Total direct holdings after transaction 75,536.1308 shares Director J. Erik Fyrwald’s position after the award

Transaction date September 21, 2026 Date of the stock award to J. Erik Fyrwald

Key Terms

Lilly Directors' Deferral Plan, stock units, separation from service

3 terms

Lilly Directors' Deferral Plan financial

"shares acquired ... deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan"

stock units financial

"shares acquired ... have been deferred in lieu of cash compensation as stock units"

Stock units are individual pieces of ownership in a company, like slices of a pie that together make up the whole business. They matter to investors because each unit represents a claim on the company’s assets, profits and sometimes voting power, and changes in the number or value of these units affect ownership percentages, potential dividends and share dilution — all of which influence an investment’s worth.

separation from service financial

"will be settled in shares of common stock following the reporting person's separation from service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Eli Lilly (LLY) report for director J. Erik Fyrwald?

Eli Lilly reported that director J. Erik Fyrwald received a grant of 8.513 shares of common stock on September 21, 2026. The award is classified as a grant, award, or other acquisition of shares rather than an open-market purchase or sale.

At what price were the new Eli Lilly (LLY) shares for J. Erik Fyrwald recorded?

The 8.513 Eli Lilly shares granted to J. Erik Fyrwald were recorded at $1,164.89 per share. This figure represents the reported value per share associated with the stock award on September 21, 2026.

How many Eli Lilly (LLY) shares does J. Erik Fyrwald hold after this Form 4 transaction?

After the September 21, 2026 award, J. Erik Fyrwald directly holds 75,536.1308 shares of Eli Lilly common stock. This total reflects his position following the acquisition of 8.513 shares reported in the Form 4 filing.

How are J. Erik Fyrwald’s new Eli Lilly (LLY) shares being treated under the company’s plans?

The newly acquired 8.513 shares have been deferred as stock units under the Lilly Directors' Deferral Plan. According to the filing, they were elected in lieu of cash compensation and will be settled in shares after Fyrwald’s separation from service.

Was the Eli Lilly (LLY) insider transaction by J. Erik Fyrwald under a Rule 10b5-1 plan?

No. The filing indicates the Rule 10b5-1 checkbox is not marked, and there is no footnote stating that the September 21, 2026 award for J. Erik Fyrwald was made under a Rule 10b5-1 or other pre-arranged trading plan.

Is J. Erik Fyrwald’s ownership in Eli Lilly (LLY) direct or indirect after this transaction?

The Form 4 reports J. Erik Fyrwald’s 75,536.1308 shares as held with direct ownership. The ownership code for this position is listed as “D”, indicating shares directly attributable to him rather than through an intermediate entity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fyrwald J Erik

(Last) (First) (Middle)

LILLY CORPORATE CENTER

(Street)

INDIANAPOLIS INDIANA 46285

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ELI LILLY & Co [ LLY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/21/2026		A		8.513(1)	A	$1,164.89	75,536.1308	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.

Remarks:

	/s/ Christopher Anderson for J. Erik Fyrwald, pursuant to authorization on file	09/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)